Active components from Lagotis brachystachya maintain uric acid homeostasis by inhibiting renal TLR4-NLRP3 signaling in hyperuricemic mice

• Published in: Inflammopharmacology Vol. 29; no. 4; pp. 1187 - 1200
• Main Authors: Zhu, Ji-Xiao, Yang, Hai-Yan, Hu, Wei-Qiong, Cheng, Jie, Liu, Yang, Yi, Li-Tao, Cheng, Hong-Yu
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.08.2021
• Subjects: Allergology; Animals; Biomedical and Life Sciences; Biomedicine; Dermatology; Dose-Response Relationship, Drug; Drugs, Chinese Herbal - isolation & purification; Drugs, Chinese Herbal - pharmacology; Drugs, Chinese Herbal - therapeutic use; Gastroenterology; Homeostasis - drug effects; Homeostasis - physiology; Hyperuricemia - drug therapy; Hyperuricemia - metabolism; Immunology; Kidney - drug effects; Kidney - metabolism; Male; Mice; NLR Family, Pyrin Domain-Containing 3 Protein - antagonists & inhibitors; NLR Family, Pyrin Domain-Containing 3 Protein - metabolism; Original Article; Pharmacology/Toxicology; Plants, Medicinal; Protein Structure, Secondary; Rheumatology; Signal Transduction - drug effects; Signal Transduction - physiology; Toll-Like Receptor 4 - antagonists & inhibitors; Toll-Like Receptor 4 - metabolism; Uric Acid - metabolism; Uric Acid - toxicity; Luteoloside; Hyperuricemia; Inflammation; Uric acid transporter; Luteolin; Apigenin
• ISSN: 0925-4692; 1568-5608
• DOI: 10.1007/s10787-021-00844-5

Lagotis brachystachya Maxim is a herb widely used in traditional Tibetan medicine. Our previous study indicated that total extracts from Lagotis brachystachya could lower uric acid levels. This study aimed to further elucidate the active components (luteolin, luteoloside and apigenin) isolated from Lagotis brachystachya and the underlying mechanism in vitro and in vivo. The results showed that treatment with luteolin and luteoloside reversed the reduction of organic anion transporter 1 (OAT1) levels, while apigenin attenuated the elevation of urate transporter 1 (URAT1) and glucose transporter 9 (GLUT9) levels in uric acid-treated HK-2 cells, which was consistent with the finding in the kidneys of potassium oxonate (PO)-induced mice. On the other hand, hepatic xanthine oxidase activity was inhibited by the components. In addition, all of these active components improved the morphology of the kidney in hyperuricemic mice. Moreover, molecular docking showed that luteolin, luteoloside and apigenin could bind Toll-like receptor 4 (TLR4) and NLR family pyrin domain containing 3 (NLRP3). Congruently, western blot analysis showed that the components inhibited TLR4/myeloid differentiation primary response 88 (MyD88)/NLRP3 signaling. In conclusion, these results indicated that luteolin, luteoloside and apigenin could attenuate hyperuricemia by decreasing the production and increasing the excretion of uric acid, which were mediated by inhibiting inflammatory signaling pathways.